LY262691
LY262691 is a selective CCK-B antagonist with antipsychotic properties. LY262691 decreases the number of spontaneously active A9 and A10 dopamine cells and can be utilized in antipsychotic research[1].
Product Specifications
CAS Number
138932-35-1
UNSPSC
12352005
Target
Cholecystokinin Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/ly262691.html
Smiles
BrC(C=C1)=CC=C1NC(N2[C@@H](C3=CC=CC=C3)[C@H](C4=CC=CC=C4)C(N2)=O)=O
Molecular Formula
C22H18BrN3O2
Molecular Weight
436.30
References & Citations
[1]Rasmussen K, et al. Cholecystokinin (CCK) and schizophrenia: the selective CCKB antagonist LY262691 decreases midbrain dopamine unit activity. Eur J Pharmacol. 1991 Dec 10;209 (1-2) :135-8.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
